Novartis Ag

Les Laboratories Servier

Les Laboratoires Servier

Ensar Halilovic

Youzhen Wang

Olivier Geneste

Giordano Caponigro

Guillaume Laurent Lessene

Fang Li

Dale Porter

Maïa Chanrion

Sebastien Jeay

Jane Visvader

Thomas Horn-Spirohn

Geoffrey Lindeman

Ana Leticia Maragno

Stephane Ferretti

Marina Konopleva

François Vaillant

Nelson Guerreiro

Joseph Lehar

Hui-Qin Wang

Giovanna Pomilio

Francois Vaillant

Donia Moujalled

Kelli-Ann Monaco

Elisabetta Marangoni

James Whittle

Delphine Merino

Andrew Wei

Astrid Jullion

Heiko Maacke

Prakash Mistry

Sneha Sanghavi

Anna Skwarska

Maia Chanrion

Christophe Meille

Claire Fabre

The present invention relates to a pharmaceutical combination comprising (a) an MDM2 inhibitor and (b) an ERK inhibitor, for use in the treatment of a cancer. This invention relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination; and kits and/or packages containing such combinations.

Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers

A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.

Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof

The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Pharmaceutical combinations

Growing community of inventors

Canton, MA, United States of America

Ensar Halilovic